Gapping up
In reaction to strong earnings/guidance: OZRK +4.6%
M&A news: SGNT +39.7% (to be acquired by Nichi-Iko Pharmaceutical for $21.75 per share), IMPV +5% (Imperva has hired bankers to consider strategic options, according to Reuters), KKR +1.0% (WME | IMG announced the acquisition of UFC, professional mixed martial arts (MMA) organization; Silver Lake and KKR are strategic investment partners)
Select EU financial related names showing strength: LYG +4.4%, BCS +4.4%, RBS +4.3%, HSBC +1.9%, PUK +1.5%
Other news: BLFS +74.5% (enters into a 10-year supply agreement with Kite Pharma (KITE) for CryoStor clinical freeze media for cells & tissues), NTIP +17% (discloses settlement of patent litigation with Apple ), CYAD +8.7% (grants exclusive license to ONO Pharma (OPHLY) for the development and commercialization of NKR-2 T-cell in Japan, Korea and Taiwan), ONVO +8.5% (Organovo and Roche (RHHBY) researchers publish data demonstrating superiority of 3D bioprinted human liver tissues in assessing drug-induced toxicity), EBIO +8.1% (cont strength following last week's IND application for EBI-031), VNET +3.8% (China Reinsurance discloses 5.4% passive stake), ESLT +3% (receives contract from Maldonado District Administration in Uruguay to provide a Safe District project worth ~$19 mln), KMI +2.8% (Kinder Morgan and Southern Company (SO) enter Southern Natural Gas pipeline strategic venture), TASR +2.5% (pulling back following strength on Friday after incident in Dallas),SBGL +1.8% (announced that it will be entering into a further consultation process with organised labour and other relevant stakeholders), VRX +1.7% (cont strength following last week's ~14% gain), TSLA +1.3% (Elon Musk tweets: 'Working on Top Secret Tesla Masterplan, Part 2. Hoping to publish later this week")
Analyst comments: GME +2.8% (upgraded to Buy from Neutral at BofA/Merrill), CAFD +2% (upgraded to Overweight from Underweight at Barclays), ORAN +1.1% (upgraded to Overweight from Neutral at JP Morgan)
In reaction to strong earnings/guidance: OZRK +4.6%
M&A news: SGNT +39.7% (to be acquired by Nichi-Iko Pharmaceutical for $21.75 per share), IMPV +5% (Imperva has hired bankers to consider strategic options, according to Reuters), KKR +1.0% (WME | IMG announced the acquisition of UFC, professional mixed martial arts (MMA) organization; Silver Lake and KKR are strategic investment partners)
Select EU financial related names showing strength: LYG +4.4%, BCS +4.4%, RBS +4.3%, HSBC +1.9%, PUK +1.5%
Other news: BLFS +74.5% (enters into a 10-year supply agreement with Kite Pharma (KITE) for CryoStor clinical freeze media for cells & tissues), NTIP +17% (discloses settlement of patent litigation with Apple ), CYAD +8.7% (grants exclusive license to ONO Pharma (OPHLY) for the development and commercialization of NKR-2 T-cell in Japan, Korea and Taiwan), ONVO +8.5% (Organovo and Roche (RHHBY) researchers publish data demonstrating superiority of 3D bioprinted human liver tissues in assessing drug-induced toxicity), EBIO +8.1% (cont strength following last week's IND application for EBI-031), VNET +3.8% (China Reinsurance discloses 5.4% passive stake), ESLT +3% (receives contract from Maldonado District Administration in Uruguay to provide a Safe District project worth ~$19 mln), KMI +2.8% (Kinder Morgan and Southern Company (SO) enter Southern Natural Gas pipeline strategic venture), TASR +2.5% (pulling back following strength on Friday after incident in Dallas),SBGL +1.8% (announced that it will be entering into a further consultation process with organised labour and other relevant stakeholders), VRX +1.7% (cont strength following last week's ~14% gain), TSLA +1.3% (Elon Musk tweets: 'Working on Top Secret Tesla Masterplan, Part 2. Hoping to publish later this week")
Analyst comments: GME +2.8% (upgraded to Buy from Neutral at BofA/Merrill), CAFD +2% (upgraded to Overweight from Underweight at Barclays), ORAN +1.1% (upgraded to Overweight from Neutral at JP Morgan)